TY  - GEN
AB  - Despite the prevalence and devastating impact of alcohol use disorder (AUD), treatment options remain inadequate with only three United States (U.S.) Food and Drug Administration (FDA) approved pharmacotherapies and limited efficacy across patient populations. Thus, development of new pharmacotherapies is necessary. Of crucial importance in designing such therapies are optimized preclinical, animal models for assessment of potential pharmacotherapies, including translationally relevant routes of administration and incorporation of the complex interactions of alcohol-related behaviors with the social environment. In this dissertation, I sought to further the translational relevance of the results by administering OXT intranasally, in line with human clinical trials. I aimed to characterize the behavioral mechanisms by recapitulating scenarios human patients face during medication-assisted maintenance of abstinence.
AU  - Potretzke, Sheena
DA  - 2022
DO  - 10.6083/g158bj21z
DO  - DOI
ID  - 9750
KW  - Alcoholism
KW  - Oxytocin
KW  - pharmacotherapy
L1  - https://digitalcollections.ohsu.edu/record/9750/files/Potretzke.Sheena.2022.pdf
L2  - https://digitalcollections.ohsu.edu/record/9750/files/Potretzke.Sheena.2022.pdf
L4  - https://digitalcollections.ohsu.edu/record/9750/files/Potretzke.Sheena.2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9750/files/Potretzke.Sheena.2022.pdf
N2  - Despite the prevalence and devastating impact of alcohol use disorder (AUD), treatment options remain inadequate with only three United States (U.S.) Food and Drug Administration (FDA) approved pharmacotherapies and limited efficacy across patient populations. Thus, development of new pharmacotherapies is necessary. Of crucial importance in designing such therapies are optimized preclinical, animal models for assessment of potential pharmacotherapies, including translationally relevant routes of administration and incorporation of the complex interactions of alcohol-related behaviors with the social environment. In this dissertation, I sought to further the translational relevance of the results by administering OXT intranasally, in line with human clinical trials. I aimed to characterize the behavioral mechanisms by recapitulating scenarios human patients face during medication-assisted maintenance of abstinence.
PB  - Oregon Health and Science University
PY  - 2022
T1  - Behavioral and molecular characterization of oxytocin's effect on alcohol consumption
TI  - Behavioral and molecular characterization of oxytocin's effect on alcohol consumption
UR  - https://digitalcollections.ohsu.edu/record/9750/files/Potretzke.Sheena.2022.pdf
Y1  - 2022
ER  -